CTLA4 and breast cancer: As follows, the non-depleting, anti-CTLA-4 Ab Tremelimumab (but not the depleting Ab Ipilimumab) showed limited activity in metastatic melanoma and breast cancer;24,53,54 what could be explained by its low capacity to deplete CTLA-4-expressing Tregs.